Tag - GLMD

Markets

Cantor cuts Galmed to neutral on limited insights into programs

Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...

August 4, 2022

Markets

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

May 26, 2022

Tag - GLMD

Cantor cuts Galmed to neutral on limited insights into programs

Maxim reduces PTs in challenging biotech market

General

More